Coming out soon
We have developed a machine learning and rule based tool called the Clinical Trial Risk Tool using natural language processing. The Clinical Trial Risk Tool allows a user to upload a trial protocol and which categorises the protocol as high, medium, or low risk of ending uninformatively.
When a pharmaceutical company develops a drug, it needs to pass through several phases of clinical trials before it can be approved by regulators.
Before the trial is run, the drug developer writes a document called a protocol. This contains key information about how long the trial will run for, what is the risk to participants, what kind of treatment is being investigated, etc.
The tool is open-source under MIT licence and it does not save any of your data.
Currently, professionals at a funding organisation read the protocols and perform a subjective assessment of the trial’s cost, complexity, and risk of ending uninformatively.
One of the most common causes of a trial ending uninformatively is underpowering. There are several indicators of high risk of uninformativeness which can be identified in a protocol, such as a lack of and or an inadequate statistical analysis plan, use of non-standard endpoints, or the use of cluster randomisation. Low-risk trials are often run by well-known institutions with external funding and an international or intercontinental array of sites. These indicators can be referred to as features or parameters.
If you would like to cite the tool alone, you can cite:
Wood TA and McNair D. Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness. Gates Open Res 2023, 7:56 doi: 10.12688/gatesopenres.14416.1.
A BibTeX entry for LaTeX users is
@article{Wood_2023,
doi = {10.12688/gatesopenres.14416.1},
url = {https://doi.org/10.12688%2Fgatesopenres.14416.1},
year = 2023,
month = {apr},
publisher = {F1000 Research Ltd},
volume = {7},
pages = {56},
author = {Thomas A Wood and Douglas McNair},
title = {Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness},
journal = {Gates Open Research}
}Blog
This post originally appeared on Fast Data Science’s blog on LinkedIn. Clinical trials are vital for advancing medical innovation, yet they often face significant hurdles, including ensuring patient safety, adhering to regulatory requirements, controlling costs, and maintaining efficiency. Traditional risk assessment methods frequently need to be revised to address these complexities. Artificial Intelligence (AI) is transforming clinical trial management, offering data-driven solutions to predict and mitigate risks. AI-powered tools like the Clinical Trial Risk Tool have revolutionised trial planning and execution.
This post originally appeared on Fast Data Science’s blog on LinkedIn. Clinical trial protocols are often long, detailed documents—sometimes 200 pages—filled with vital information about sample size, treatment methods, and statistical plans. These protocols ensure the effective conduct of trials, but their complexity increases the time needed for manual reviews and the risk of human error. This is where Natural Language Processing (NLP) steps in. NLP enables machines to “read” unstructured data, such as clinical trial protocols, and extract key insights.
This post originally appeared on Fast Data Science’s blog on LinkedIn. Clinical trials, the backbone of medical science advancement, often grapple with high costs, complexity, and lengthy timelines. Fast Data Science presents Fast Clinical AI, a game-changing solution that harnesses the power of Natural Language Processing (NLP) and predictive modelling to tackle these challenges head-on. Streamlined Data Extraction and Analysis: Fast Clinical AI automates the extraction of critical information from trial protocols, significantly reducing manual efforts.